EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PLGA nanocapsules as a delivery system for a recombinant LRP ‐based therapeutic

Martin Bernert, Monique J Bignoux, Chandni Madhav, Sichumiso Gqeba, Tyrone C Otgaar, Gavin Morris, Stefan F T Weiss iD, Eloise Ferreira iD

FEBS Open Bio · 2024

DOI: 10.1002/2211-5463.13809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, 2024. Verfasst von Martin Bernert und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Nanocapsules, Polylactic Acid-Polyglycolic Acid Copolymer, Cell Survival. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technology and Innovation Agency, Department of Science and Innovation (DSI) South Africa, Cancer Association of South Africa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Telomerase activity is directly affected by the laminin receptor precursor (LRP) protein, a highly conserved nonintegrin transmembrane receptor, which has been shown to have therapeutic effects in ageing, and age‐related diseases. Recently, it has been found that overexpression of LRP‐FLAG, by plasmid transfection, leads to a significant increase in telomerase activity in cell culture models. This may indicate that upregulation of LRP can be used to treat various age‐related diseases. However, transfection is not a viable treatment strategy for patients. Therefore, we present a nanoencapsulated protein‐based drug synthesised using poly(lactic‐co‐glycolic acid) (PLGA) nanocapsules for delivery of the 37 kDa LRP protein therapeutic. PLGA nanocapsules were synthesised using the double emulsification‐solvent evaporation technique. Different purification methods, including filtration and centrifugation, were tested to ensure that the nanocapsules were within the optimal size range, and the BCA assay was used to determine encapsulation efficiency. The completed drug was tested in a HEK‐293 cell culture model, to investigate the effect on cell viability, LRP protein levels and telomerase activity. A significant increase in total LRP protein levels with a concomitant increase in cell viability and telomerase activity was observed. Due to the observed increase in telomerase activity, this approach could represent a safer alternative to plasmid transfection for the treatment of age‐related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanocapsulesPolylactic Acid-Polyglycolic Acid CopolymerCell SurvivalHumansHEK293 CellsRecombinant ProteinsTelomerasePolyglycolic AcidDrug Delivery SystemsLactic AcidReceptors, Laminin

Stichwörter der Autor:innen

LRPPLGAnanoparticletelomerasetherapeutic

Substanzen

NanocapsulesPolylactic Acid-Polyglycolic Acid CopolymerRecombinant ProteinsTelomerasePolyglycolic AcidLactic AcidReceptors, Laminin

Autor:innen und Institutionen

  • School of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Stefan F T Weiss, Eloise Ferreira

Förderung

  • Technology and Innovation Agency, Department of Science and Innovation (DSI) South Africa
  • Cancer Association of South Africa

Zitieren

APA

Bernert, M., Bignoux, M. J., Madhav, C., Gqeba, S., Otgaar, T. C., Morris, G., Weiss, S. F. T., & Ferreira, E. (2024). PLGA nanocapsules as a delivery system for a recombinant LRP ‐based therapeutic. FEBS Open Bio. https://doi.org/10.1002/2211-5463.13809

Vancouver

Bernert M, Bignoux MJ, Madhav C, Gqeba S, Otgaar TC, Morris G, et al. PLGA nanocapsules as a delivery system for a recombinant LRP ‐based therapeutic. FEBS Open Bio. 2024. doi:10.1002/2211-5463.13809

BibTeX
@article{Bernert2024,
  author = {Bernert, Martin and Bignoux, Monique J and Madhav, Chandni and Gqeba, Sichumiso and Otgaar, Tyrone C and Morris, Gavin and Weiss, Stefan F T and Ferreira, Eloise},
  title = {PLGA nanocapsules as a delivery system for a recombinant LRP ‐based therapeutic},
  journal = {FEBS Open Bio},
  year = {2024},
  doi = {10.1002/2211-5463.13809}
}
Kostenlos starten →